keyword
MENU ▼
Read by QxMD icon Read
search

Nepafenac

keyword
https://www.readbyqxmd.com/read/28774934/management-of-postoperative-inflammation-after-cataract-and-complex-ocular-surgeries-a-systematic-review-and-delphi-survey
#1
REVIEW
Florent Aptel, Cyrille Colin, Sema Kaderli, Catherine Deloche, Alain M Bron, Michael W Stewart, Christophe Chiquet
Prevention and management of postoperative ocular inflammation with corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) have been evaluated in several randomised controlled trials (RCTs). However, neither consensus regarding the efficacies of different regimens nor established guidelines are currently available. This has resulted in different practice patterns throughout the world. A systematic literature review found that for the management of postcataract inflammation nepafenac produced a positive outcome in three of three RCTs (3/3), as did ketorolac (1/1), bromfenac (7/7), loteprednol (3/3) and difluprednate (6/6), but not flurbiprofen (0/1)...
August 3, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28740734/effect-of-topical-nepafenac-on-central-foveal-thickness-following-panretinal-photocoagulation-in-diabetic-patients
#2
Nahla B Abu Hussein, Ahmed A Mohalhal, Dalia A Ghalwash, Ahmed A Abdel-Kader
PURPOSE: To evaluate effectiveness of topical nepafenac in reducing macular edema following panretinal photocoagulation (PRP). DESIGN: Prospective randomized double-blinded controlled study. METHODS: Sixty eyes of 60 patients having proliferative or severe nonproliferative diabetic retinopathy had PRP. Patients were then divided into two groups: nepafenac group (30 eyes) receiving 1% topical nepafenac eye drops for 6 months and control group (30 eyes) receiving carboxymethylcellulose eye drops for 6 months...
2017: Journal of Ophthalmology
https://www.readbyqxmd.com/read/28699051/-assessing-the-added-benefit-of-new-ophthalmic-drugs-which-additional-insights-can-be-extracted-from-the-early-benefit-assessment
#3
REVIEW
M Appelrath, G Glaeske
Until now six ophthalmic agents have undergone the German early benefit assessment according to § 35a Social Security Code (SGB) V in a total of eleven indications. Only one agent (ocriplasmin) was recognized by the Federal Joint Committee as having an added benefit based on submitted study data for a subpopulation (indication of a considerable added benefit, limited for 5 years) and another agent, idebenone, received an added benefit due to its orphan drug designation (proof of a not quantifiable added benefit, limited for 2 years)...
July 11, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28653209/-early-onset-of-fingolimod-associated-macular-edema
#4
D Schelenz, I Kleiter, J Schöllhammer, J Rehrmann, M Elling, H B Dick, V Kakkassery
BACKGROUND: Fingolimod, a disease-modifying sphingosine 1‑phosphate receptor modulator, which was approved in Germany in 2011, decreases the relapse rate and reduces neuroinflammation in patients with relapsing-remitting multiple sclerosis. Macular edema is a well-known ocular side effect of fingolimod therapy. Specific intervals for ophthalmologic check-ups after starting fingolimod and definite treatment schedules for fingolimod-associated macular edema are, however, still lacking...
June 26, 2017: Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
https://www.readbyqxmd.com/read/28603408/efficacy-of-nepafenac-ophthalmic-suspension-0-1-in-improving-clinical-outcomes-following-cataract-surgery-in-patients-with-diabetes-an-analysis-of-two-randomized-studies
#5
Rishi P Singh, Giovanni Staurenghi, Ayala Pollack, Adeniyi Adewale, Thomas M Walker, Dana Sager, Robert Lehmann
OBJECTIVE: To assess the efficacy of nepafenac 0.1% ophthalmic suspension in improving the clinical outcomes following cataract surgery (CS) in patients with nonproliferative diabetic retinopathy. METHODS: In two similar multicenter, randomized studies, patients received either nepafenac 0.1% or vehicle, instilled three times daily starting a day prior to surgery and continuing for 90 days postoperatively. A post hoc analysis of these two studies was conducted to assess 1) the likelihood for development of postoperative macular edema (ME), based on the percentage of patients who developed ME (≥30% increase from preoperative baseline in central subfield macular thickness) within 90 days following CS and 2) best-corrected visual acuity (BCVA) endpoints, including the percentage of patients with a BCVA improvement of ≥15 letters from preoperative baseline to Day 14 and maintained through Day 90...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28493461/ophthalmic-nepafenac-use-in-the-netherlands-and-denmark
#6
Andrea V Margulis, Eline Houben, Jesper Hallas, Jetty A Overbeek, Anton Pottegård, Tobias Torp-Pedersen, Susana Perez-Gutthann, Alejandro Arana
PURPOSE: To describe nepafenac use in the Netherlands and Denmark with reference to its approved indications. For context, we also describe the use of ketorolac and diclofenac. METHODS: We identified users in the PHARMO Database Network (the Netherlands, 2008-2013) and the Danish national health registers (Denmark, 1994-2014). We described prevalence of cataract surgery and duration of use in patients with cataract surgery with and without diabetes. RESULTS: In the Netherlands, 9530 nepafenac users (mean age, 71 years; 60% women) contributed 12 691 therapy episodes, of which 21% had a recently recorded cataract surgery...
August 2017: Acta Ophthalmologica
https://www.readbyqxmd.com/read/28407163/effect-of-topical-nonsteroidal-anti-inflammatory-drugs-on-pupillary-size-during-uncomplicated-cataract-surgery
#7
Alejandro Rodríguez-García, Julio C Hernández-Camarena, Gilberto R López-Jaime, José A Nava-García
PURPOSE: To compare the effectiveness of three different topical nonsteroidal anti-inflammatory drugs (NSAIDs) in inhibiting surgically induced miosis during uncomplicated cataract phacoemulsification. METHODS: Prospective, randomized, double-masked comparative study of patients aged 40 years or older with grades II to III cataracts (Lens Opacities Classification System) and no other comorbidities. Participants were randomized into four groups: 0.1% nepafenac, 0...
April 1, 2017: Journal of Refractive Surgery
https://www.readbyqxmd.com/read/28367202/effect-of-topical-nepafenac-in-prevention-of-macular-edema-after-cataract-surgery-in-patients-with-non-proliferative-diabetic-retinopathy
#8
Muhammad Haroon Sarfraz, Rana Intisar Ul Haq, Mohammad Asim Mehboob
OBJECTIVE: To determine the efficacy of topical Nepafenac (0.1%), administered post-operatively in prevention of Macular Edema (ME), after cataract surgery in patients with Non-Proliferative Diabetic Retinopathy (NPDR). METHODS: This randomized control trial was conducted at Armed Forces Institute of Ophthalmology (AFIO), Rawalpindi from Sep 2015 to Sep 2016. Sixty eyes of 60 patients with NPDR underwent phacoemulsification with intraocular lens implantation. Group 1 received 0...
January 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/28320481/cystoid-macular-edema-associated-with-preservative-free-latanoprost-after-uncomplicated-cataract-surgery-case-report-and-review-of-the-literature
#9
REVIEW
Olga E Makri, Foteini N Tsapardoni, Panagiotis Plotas, Nikistratos Ifantis, Paraskevi T Xanthopoulou, Constantine D Georgakopoulos
BACKGROUND: Cystoid macular edema associated with latanoprost administration has been reported in patients after complicated cataract surgery with coexisting risk factors. We present the first case of preservative free latanoprost associated cystoid macular edema that occurred many months after uncomplicated cataract surgery. CASE PRESENTATION: A 65-year old Caucasian female presented in the Outpatients Clinic complaining of reduced vision and metamorphopsia in the right eye...
March 20, 2017: BMC Research Notes
https://www.readbyqxmd.com/read/28268098/nepafenac-0-3-after-cataract-surgery-in-patients-with-diabetic-retinopathy-results-of-2-randomized-phase-3-studies
#10
RANDOMIZED CONTROLLED TRIAL
Rishi P Singh, Robert Lehmann, Joseph Martel, Kevin Jong, Ayala Pollack, Alexis Tsorbatzoglou, Giovanni Staurenghi, Guadalupe Cervantes-Coste Cervantes, Louis Alpern, Satish Modi, Liza Svoboda, Adeniyi Adewale, Glenn J Jaffe
PURPOSE: To demonstrate the efficacy and safety of once-daily nepafenac 0.3% ophthalmic suspension versus vehicle, based on clinical outcomes, after cataract surgery in patients with diabetes. DESIGN: Two prospective, randomized, multicenter, double-masked, vehicle-controlled phase 3 studies. PARTICIPANTS: Total, 615 patients in study 1 and 605 patients in study 2. METHODS: Patients were randomized (1:1) to topical nepafenac 0...
June 2017: Ophthalmology
https://www.readbyqxmd.com/read/28253334/comparison-of-the-efficacy-and-patients-tolerability-of-nepafenac-and-ketorolac-in-the-treatment-of-ocular-inflammation-following-cataract-surgery-a-meta-analysis-of-randomized-controlled-trials
#11
Xinyu Zhao, Song Xia, Erqian Wang, Youxin Chen
As a new ophthalmic non-steroidal anti-inflammatory drug (NSAID) with prodrug structure, Nepafenac was supposed to have a better efficacy than conventional NSAIDs both in patients' tolerability and ocular inflammation associated with cataract surgery. However, many current studies reached contradictory conclusions on the superiority of Nepafenac over Ketorolac. The objective of our study is to evaluate the efficacy and patients' tolerability of Nepafenac and Ketorolac following cataract surgery. To clarify this, we conducted a meta-analysis of randomized controlled trials...
2017: PloS One
https://www.readbyqxmd.com/read/28219426/pseudophakic-cystoid-macular-edema-prevention-and-risk-factors-prospective-study-with-adjunctive-once-daily-topical-nepafenac-0-3-versus-placebo
#12
RANDOMIZED CONTROLLED TRIAL
Sean McCafferty, April Harris, Corin Kew, Tala Kassm, Lisa Lane, Jason Levine, Meisha Raven
BACKGROUND: Define the effectiveness of a topical non-steroidal anti-inflammatory drug (NSAID) added to topical steroid use after uncomplicated phacoemulsification for the prevention of pseudophakic cystoid macular edema (PCME) using a prospective, randomized, double-masked, placebo-controlled clinical study. METHODS: Eyes (1000) were randomized to placebo (497) or nepafenac 0.3% (503) used once daily, post-operatively for 5 weeks at two ophthalmology clinics. Diagnosis of PCME was made by clinical, ocular coherence tomography (OCT), and with fluorescein angiography confirmation...
February 20, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28130595/the-comparative-efficacy-and-safety-of-topical-non-steroidal-anti-inflammatory-drugs-for-the-treatment-of-anterior-chamber-inflammation-after-cataract-surgery-a-systematic-review-and-network-meta-analysis
#13
REVIEW
Ping Duan, Yong Liu, Jiawen Li
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are a class of anti-inflammatory drugs that are used in ophthalmologic surgery. These drugs do not have a steroid structure, but can inhibit surgery-induced miosis, anterior chamber inflammation, and cystoid macular edema (CME). However, the application of NSAIDs remains controversial. Therefore, we performed a meta-analysis to assess the efficacy and safety of NSAIDs for the treatment of anterior chamber inflammation after cataract surgery...
April 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28080174/the-use-of-topical-non-steroidal-anti-inflammatory-drugs-for-uveitic-cystoid-macular-edema
#14
Harry Petrushkin, Duncan Rogers, Carlos Pavesio
The use of topical non-steroidal anti-inflammatory drugs in the management of uveitic cystoid macular edema is controversial. In this letter, we review the literature and report our results from a retrospective case series of 281 patients taking topical nepafenac 0.1% for uveitic cystoid macular edema between 2010 and 2016. Over a 4-month period, there was a modest improvement in best-corrected visual acuity (0.66 ± 3.7 logMAR) and central macular thickness (69.8 ± 132.5 μm). Patients with idiopathic anterior uveitis and HLA-B*27-associated anterior uveitis recovered more vision while taking topical nepafenac 0...
January 12, 2017: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/27971626/cost-effectiveness-of-nepafenac-3-mg-ml-for-the-reduction-in-risk-of-post-operative-macular-oedema-associated-with-cataract-surgery-from-uk-nhs-perspective
#15
A Mullins, P Meijer, R Airey, P Gunda, J Banhazi
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27911428/-macular-edema-after-prior-brachytherapy-in-a-diabetic-retinopathy-patient-clinical-case
#16
S A Ignat'ev, O N Steshenko, Ya N Khionidi
The authors describe a case of radiation retinopathy after brachytherapy for uveal melanoma successfully treated with nepafenac 0.1%, a non-steroidal anti-inflammotory agent.
2016: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/27843229/a-comparative-study-of-various-topical-nonsteroidal-anti-inflammatory-drugs-to-steroid-drops-for-control-of-post-cataract-surgery-inflammation
#17
Anu Malik, Anup Sadafale, Yogesh Kumar Gupta, Alka Gupta
BACKGROUND: Postoperative inflammation continues to be a cause of patient discomfort, delayed recovery, and in some cases, suboptimal visual results. Topical nonsteroidal anti-inflammatory drugs (NSAIDs) and steroid are commonly used in the management and prevention of noninfectious ocular inflammation following cataract surgery. AIMS: The aim was to study the safety and efficacy of various NSAIDs drops for control of postoperative inflammation following cataract surgery and compare with steroid eye drops in a patient following cataract surgery...
September 2016: Oman Journal of Ophthalmology
https://www.readbyqxmd.com/read/27801522/prophylactic-non-steroidal-anti-inflammatory-drugs-for-the-prevention-of-macular-oedema-after-cataract-surgery
#18
REVIEW
Blanche X Lim, Chris Hl Lim, Dawn K Lim, Jennifer R Evans, Catey Bunce, Richard Wormald
BACKGROUND: Macular oedema (MO) is the accumulation of extracellular fluid in the central retina (the macula). It may occur after cataract surgery and may give rise to poor visual outcome, with reduced visual acuity and distortion of the central vision. MO is often self-limiting with spontaneous resolution, but a small proportion of people with chronic persistent MO may be difficult to treat. Chronic oedema may lead to the formation of cystic spaces in the retina termed 'cystoid macular oedema' (CMO)...
November 1, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27771823/effect-of-nepafenac-on-the-foveal-profile-of-glaucomatous-patients-undergoing-phacoemulsification
#19
Elena Milla, Oana Stirbu, Isabel Jimenez Franco, Santiago J García Hernández, Jose Rios, Susana Duch
PURPOSE: Retrospective, pilot study to determine whether nepafenac treatment pre- and postcataract surgery in glaucoma patients using topical hypotensive agents minimized cystoid macular edema by comparing pre- and postsurgical foveal characteristics, as in some cases these agents cannot be withdrawn and, hypothetically, their inflammatory effect on the fovea could be neutralized by the addition of nepafenac. METHODS: Patients were divided into two subgroups depending on whether or not topical nepafenac was added to the surgical protocol (NEP = nepafenac group and nNEP = non nepafenac group)...
October 22, 2016: International Ophthalmology
https://www.readbyqxmd.com/read/27766540/topical-nonsteroidal-anti-inflammatory-drugs-as-adjuvant-therapy-in-the-prevention-of-macular-edema-after-cataract-surgery
#20
Nicola Cardascia, Carmela Palmisano, Tersa Centoducati, Giovanni Alessio
PURPOSE: The purpose of the study was to assess adjuvant treatment with topical nonsteroidal anti-inflammatory drugs (NSAIDs) (0.9 % bromfenac, 0.1 % nepafenac, 0.5 % indomethacin, or 0.1 % diclofenac) in addition to topical steroidal treatment with 0.1 % dexamethasone and 0.3 % netilmicin for prevention of cystoid macular edema (CME) after uneventful small incision cataract extraction with foldable intraocular lens (IOL) implantation. SETTING: Institute of Ophthalmology, Department of Scienze Mediche di Base, Neuroscienze ed Organi di Senso, Aldo Moro University, Policlinico Consorziale di Bari, Bari, Italy...
October 20, 2016: International Ophthalmology
keyword
keyword
81637
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"